Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 139
Filtrar
1.
J Dermatol ; 51(6): 752-758, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38619178

RESUMO

The Index for Facial Angiofibromas (IFA), a novel scoring system for angiofibromas, has been validated in patients with tuberous sclerosis complex (TSC). The objective of this analysis was to further validate the IFA using data from a clinical trial of topical sirolimus in patients with TSC. This was an analysis of photographs from a Phase III trial conducted in Japan (NCT02635789). Patients (n = 62) were randomized 1:1 to receive sirolimus or placebo gel for 12 weeks. Changes in angiofibromas were independently assessed using the primary composite endpoint, the Facial Angiofibroma Severity Index (FASI), and the IFA. Thresholds for a clinically meaningful change in IFA score were evaluated using receiver operating characteristic (ROC) analysis. The IFA scores had good-to-excellent inter-assessor reliability, very high intra-assessor reliability, and could be used to evaluate the distribution of disease severity at baseline. High correlations were observed between the categorized change from baseline in IFA scores and the primary composite endpoint (Kendall's coefficient of concordance, W = 0.8655, p < 0.0001), and between the change from baseline in IFA and FASI scores (Kendall's coefficient of concordance, W = 0.745, p < 0.0001). By ROC analysis, an optimal IFA cut-off point of 1.667 was determined to distinguish patients with markedly improved or improved angiofibromas from those with slightly improved or unchanged angiofibromas (area under the curve 0.937) as determined by the primary composite endpoint. The IFA score is potentially clinically useful because of its high validity and reliability. A decrease in score from baseline of ≥1.667 may be considered clinically meaningful.


Assuntos
Angiofibroma , Neoplasias Faciais , Géis , Índice de Gravidade de Doença , Sirolimo , Esclerose Tuberosa , Humanos , Esclerose Tuberosa/tratamento farmacológico , Esclerose Tuberosa/diagnóstico , Esclerose Tuberosa/complicações , Angiofibroma/tratamento farmacológico , Angiofibroma/diagnóstico , Sirolimo/administração & dosagem , Sirolimo/uso terapêutico , Masculino , Feminino , Neoplasias Faciais/tratamento farmacológico , Neoplasias Faciais/patologia , Reprodutibilidade dos Testes , Adolescente , Adulto , Adulto Jovem , Resultado do Tratamento , Método Duplo-Cego , Fotografação , Japão , Curva ROC
2.
Sci Rep ; 14(1): 2791, 2024 02 02.
Artigo em Inglês | MEDLINE | ID: mdl-38307882

RESUMO

Zinc deficiency, affecting more than 2 billion people globally, poses a significant public health burden due to its numerous unfavorable effects, such as impaired immune function, taste and smell disorders, pneumonia, growth retardation, visual impairment, and skin disorders. Despite its critical role, extensive large-scale studies investigating the correlation between patient characteristics and zinc deficiency still need to be completed. We conducted a retrospective, cross-sectional observational study using a nationwide Japanese claims database from January 2019 to December 2021. The study population included 13,100 patients with available serum zinc concentration data, excluding individuals under 20 and those assessed for zinc concentrations after being prescribed zinc-containing medication. Significant associations with zinc deficiency were noted among older adults, males, and inpatients. Multivariate analysis, adjusting for age and sex, indicated significant associations with comorbidities, including pneumonitis due to solids and liquids with an adjusted Odds Ratio (aOR) of 2.959; decubitus ulcer and pressure area (aOR 2.403), sarcopenia (aOR 2.217), COVID-19 (aOR 1.889), and chronic kidney disease (aOR 1.835). Significant association with medications, including spironolactone (aOR 2.523), systemic antibacterials (aOR 2.419), furosemide (aOR 2.138), antianemic preparations (aOR 2.027), and thyroid hormones (aOR 1.864) were also found. These results may aid clinicians in identifying patients at risk of zinc deficiency, potentially improving care outcomes.


Assuntos
Desnutrição , Zinco , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Transversais , Demografia , Japão/epidemiologia , Desnutrição/epidemiologia , Estudos Retrospectivos , Zinco/deficiência , Bases de Dados Factuais
3.
Biol Trace Elem Res ; 202(5): 1937-1947, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-37658952

RESUMO

Trace elements are minerals that are present in very low concentrations in the human body and yet are crucial for a wide range of physiological functions. Zinc, the second most abundant trace element, is obtained primarily from the diet. After being taken up in the intestine, zinc is distributed to various target organs, where it plays key roles in processes such as immunity, protein folding, apoptosis, and antioxidant activity. Given the important role of zinc in a wide range of enzymatic reactions and physiological processes, zinc deficiency has been identified in a variety of diseases, notably cancer. In recent years, multiple meta-analyses and reviews looking at zinc levels in individual cancer types have been published, as have a plethora of primary studies demonstrating a link between low zinc levels and specific types of cancer. In this review, we summarize recent evidence implicating low zinc concentrations in serum or tissues as a characteristic in a wide range of cancers. We also discuss preliminary findings indicating that zinc level measurement could ultimately become a useful clinical tool for cancer diagnosis and predicting outcomes in patients with cancer. Finally, we suggest future directions for further elucidating the role of zinc deficiency in cancer development and progression.


Assuntos
Desnutrição , Neoplasias , Oligoelementos , Humanos , Minerais , Oligoelementos/metabolismo , Zinco , Dieta
4.
J Invasive Cardiol ; 35(10)2023 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-37984323

RESUMO

OBJECTIVES: Burr entrapment is a potentially life-threatening complication of rotational atherectomy (RA). However, owing to its infrequency, there have been no major reports on burr entrapment. This study aimed to evaluate the incidence, treatment, and outcomes of burr entrapment. METHODS: This multicenter retrospective study analyzed patients who had undergone percutaneous coronary interventions (PCIs) and were treated by RA between May 2013 and March 2022. RESULTS: Of the 22 640 PCI procedures, RA was performed in 3195 patients (14.1%), among whom burr entrapment occurred in 22 patients (0.69%). The mean patient age was 78 ± 8.7 years; 64% were male, and 32% were on dialysis. The entrapped burr size was 1.7 ± 0.2 mm, and the burr/artery ratio was 0.6 ± 0.1. In 20 patients (91%), the burr was extracted by strong manual pullback. The other patients underwent balloon angioplasty at the site of the entrapped burr, which might have provided space for successful burr withdrawal. Major adverse cardiac events occurred in 23% of patients. Tamponade requiring pericardiocentesis occurred in two patients (9%). No patients required emergency surgery or suffered an in-hospital death. CONCLUSIONS: Burr entrapment occurred in 0.69% of patients who had undergone RA. Most burrs were extracted by a strong manual pullback. None required emergency surgery, and there were no in-hospital deaths. The results provide a treatment approach and prognosis for burr stuck in the use of RA.


Assuntos
Angioplastia Coronária com Balão , Aterectomia Coronária , Doença da Artéria Coronariana , Intervenção Coronária Percutânea , Humanos , Masculino , Idoso , Idoso de 80 Anos ou mais , Feminino , Aterectomia Coronária/efeitos adversos , Aterectomia Coronária/métodos , Intervenção Coronária Percutânea/efeitos adversos , Intervenção Coronária Percutânea/métodos , Estudos Retrospectivos , Mortalidade Hospitalar , Angioplastia Coronária com Balão/métodos , Resultado do Tratamento , Doença da Artéria Coronariana/diagnóstico , Doença da Artéria Coronariana/cirurgia , Doença da Artéria Coronariana/etiologia , Angiografia Coronária/métodos
5.
Infect Dis (Lond) ; 55(12): 857-873, 2023 12.
Artigo em Inglês | MEDLINE | ID: mdl-37729076

RESUMO

BACKGROUND: Granulocyte-macrophage colony stimulating factor (GM-CSF) inhalation may alleviate pulmonary inflammation caused by viral pneumonia. To investigate this, we evaluated its efficacy on COVID-19 pneumonia. METHODS: This double-blind, randomised, placebo-controlled study (ClinicalTrials.gov: NCT04642950) evaluated patients in the first half of 2021 at seven Japanese hospitals. Hospitalised patients with COVID-19 pneumonia with moderate hypoxaemia inhaled sargramostim or placebo for 5 days. The primary endpoint was days to achieve a ≥ 2-category improvement from baseline on a modified 7-category ordinal scale. Secondary endpoints included degree of oxygenation, defined by amount of oxygen supply, and serum CCL17 level. RESULTS: Seventy-five patients were randomly assigned in a 2:1 ratio to receive sargramostim or placebo, of which 47 and 23 were analysed, respectively. No difference was observed between groups regarding the primary endpoint (8.0 and 7.0 days for sargramostim and placebo, respectively) or in the secondary endpoints, except for CCL17. A post hoc sub-analysis indicated that endpoint assessments were influenced by concomitant corticosteroid therapy. When the cumulative corticosteroid dose was ≤500 mg during Days 1-5, recovery and oxygenation were faster in the sargramostim group than for placebo. Bolus dose corticosteroids were associated with temporarily impaired oxygenation and delayed clinical recovery. The increase in serum CCL17, a candidate prognostic factor, reflected improvement with sargramostim inhalation. The number of adverse events was similar between groups. Two serious adverse events were observed in the sargramostim group without causal relation. CONCLUSIONS: Inhaled sargramostim was likely to be effective for COVID-19 pneumonia unless the concomitant corticosteroid dose was high.


Assuntos
COVID-19 , Humanos , Fator Estimulador de Colônias de Granulócitos e Macrófagos/efeitos adversos , Corticosteroides/uso terapêutico , Esteroides , Método Duplo-Cego , Resultado do Tratamento
6.
Medicine (Baltimore) ; 102(3): e32703, 2023 Jan 20.
Artigo em Inglês | MEDLINE | ID: mdl-36701704

RESUMO

In this study, we analyzed blood zinc concentration in patients with various cancer types and the degree of improvement in relation to the underlying disease following treatment with zinc preparations. Serum zinc levels of 530 cancer patients whose blood zinc levels were measured at our hospital from 2016 to 2021 were retrospectively examined in accordance with the primary disease. Changes in zinc levels were analyzed in 155 patients whose zinc levels had been measured on 2 or more occasions in accordance with whether they had received zinc preparations. In addition, the concentration course of zinc before and after zinc formulation administration in 73 patients was examined in accordance with the presence or absence of liver cirrhosis complications. Mean serum zinc levels were below normal in all carcinomas measured, and zinc levels were significantly lower in cirrhosis-hepatocarcinoma cases than in other primary disease cases. Furthermore, serum zinc levels in patients who did not receive zinc preparations decreased significantly over time. In patients who received zinc preparations, the elevated levels of zinc after treatment were significantly lower in patients with cirrhosis than in those without cirrhosis. There was a weak inverse correlation between pre-dose zinc concentration and increased zinc concentration in patients with cirrhosis. In the analysis of covariance, the presence of liver cirrhosis was predominantly correlated with elevated zinc per dose. In summary, serum zinc levels in cancer patients are low and especially low in cancer patients with liver cirrhosis compared with those without cirrhosis after the administration of zinc preparations.


Assuntos
Carcinoma Hepatocelular , Neoplasias Hepáticas , Humanos , Estudos Retrospectivos , Cirrose Hepática , Zinco/uso terapêutico , Carcinoma Hepatocelular/tratamento farmacológico , Neoplasias Hepáticas/tratamento farmacológico
8.
Nat Commun ; 13(1): 5388, 2022 Sep 14.
Artigo em Inglês | MEDLINE | ID: mdl-36104375

RESUMO

An unambiguous observation of the Bose-Einstein condensation (BEC) of excitons in a photoexcited bulk semiconductor and elucidation of its inherent nature have been longstanding problems in condensed matter physics. Here, we observe the quantum phase transition and a Bose-Einstein condensate appearing in a trapped gas of 1s paraexcitons in bulk Cu2O below 400 mK, by directly visualizing the exciton cloud in real space using mid-infrared induced absorption imaging that we realized in a dilution refrigerator. Our study shows that the paraexciton condensate is undetectable by conventional luminescence spectroscopy. We find an unconventionally small condensate fraction of 0.016 with the spatial profile of the condensate well described by mean-field theory. Our discovery of this new type of BEC in the purely matter-like exciton system interacting with a cold phonon bath could pave the way for the classification of its long-range order, and for essential understanding of quantum statistical mechanics of non-equilibrium open systems.

9.
J Invasive Cardiol ; 34(9): E678-E682, 2022 09.
Artigo em Inglês | MEDLINE | ID: mdl-35969840

RESUMO

OBJECTIVES: This study aimed to evaluate the clinical effectiveness and outcomes of treatment with the subintimal tracking and re-entry technique for stent-jailed side branch (SB-STAR). SB occlusion is a serious complication of percutaneous coronary intervention (PCI). However, conventional strategies may fail to recanalize the stent-jailed SB. METHODS: We retrospectively analyzed consecutive patients who underwent elective PCI and were treated with SB-STAR at the Sapporo Cardiovascular Clinic in Japan. SB was treated for severe stenosis, reduced thrombolysis in myocardial infarction flow grade, or ischemic signs after main vessel stenting. Technical success during the procedure and clinical and angiographic follow-up findings at 6 months were analyzed. RESULTS: Of the 13,431 PCI procedures performed between January 2016 and June 2021, SB-STAR was performed in 10 patients. The angiographic success rate was 100%. At the 6-month follow-up, no deaths or target-vessel revascularizations had occurred. All patients underwent angiographic follow-up, and 8 of the 10 patients (80%) who underwent SB-STAR had confirmed patency. CONCLUSIONS: SB-STAR can be a bailout strategy to improve the critical situation of stent-jailed SB occlusion. At 6-month follow-up, the SB-STAR had good patency as well as good clinical outcomes.


Assuntos
Angioplastia Coronária com Balão , Doença da Artéria Coronariana , Infarto do Miocárdio , Intervenção Coronária Percutânea , Angioplastia Coronária com Balão/métodos , Angiografia Coronária/métodos , Doença da Artéria Coronariana/terapia , Humanos , Intervenção Coronária Percutânea/efeitos adversos , Estudos Retrospectivos , Stents , Resultado do Tratamento
10.
Tohoku J Exp Med ; 258(3): 177-182, 2022 Oct 25.
Artigo em Inglês | MEDLINE | ID: mdl-36002252

RESUMO

Perimyocarditis is a rare and serious cardiac complication following COVID-19 vaccination. Young males are most at risk after the second dose. With the introduction of the booster (third) dose, some reports have focused on the risk of perimyocarditis after a booster dose. However, no currently available report in Japan has comprehensively described this phenomenon. A healthy 14-year-old Japanese male, who had completed a two-dose primary series of the BNT162b2 (Pfizer-BioNTech) vaccine six months prior, developed fever and chest pain within 24 hours after a homologous booster dose. He was transferred to our institute because of worsening chest pain. A multiplex PCR test showed no evidence of active viral infections, including SARS-CoV-2. Electrocardiography revealed ST-segment elevation in almost all leads, suggesting pericarditis. Echocardiography showed normal systolic function. Laboratory data demonstrated C-reactive protein levels of 8.8 mg/dL and elevated cardiac damage markers (troponin T, 1.9 ng/mL; creatine phosphokinase, 1527 U/L; MB isoenzyme, 120 U/L), suggesting myocarditis. He was diagnosed with perimyocarditis associated with the booster dose, which was confirmed by cardiac magnetic resonance imaging four days after initial symptoms. Chest pain improved spontaneously along with a resolution of electrocardiographic findings and laboratory data within several days. He was discharged eight days after admission. Perimyocarditis is less frequent after a booster dose than after primary doses. In this case, the patient with booster-dose-associated perimyocarditis showed favorable clinical course without severe sequelae. The patient's clinical course was consistent with findings on previous large-scale reports on primary-dose-associated perimyocarditis and case series on booster-dose-associated perimyocarditis.


Assuntos
Vacina BNT162 , Vacinas contra COVID-19 , Miocardite , Adolescente , Humanos , Masculino , Vacina BNT162/efeitos adversos , Proteína C-Reativa/metabolismo , Dor no Peito , COVID-19/complicações , Vacinas contra COVID-19/efeitos adversos , Creatina Quinase , Isoenzimas , Japão , Miocardite/diagnóstico , Miocardite/etiologia , SARS-CoV-2 , Troponina T
11.
Nihon Shokakibyo Gakkai Zasshi ; 119(8): 761-767, 2022.
Artigo em Japonês | MEDLINE | ID: mdl-35944994

RESUMO

A 61-year-old man was admitted due to alcoholic liver cirrhosis, portal vein thrombosis, hepatocellular carcinoma, and chronic pancreatitis. The patient's portal vein thrombosis improved with anticoagulant therapy. Serum amylase gradually increased, but there was no abdominal pain. The patient was placed under observation. The pain in both ankle and knee joints appeared on nine days after admission. Multiple osteonecrotic lesions of both elbows, both knees and both ankle joints were examined using 99mTc bone scintigraphic examinations. Magnetic resonance of the right ankle joint showed osteonecrosis. The pain of the right ankle joint improved with a decrease of serum amylase. We report that this is a rare case of multiple osteonecrosis caused by exacerbation of chronic pancreatitis.


Assuntos
Carcinoma Hepatocelular , Neoplasias Hepáticas , Osteonecrose , Pancreatite Crônica , Trombose Venosa , Amilases , Carcinoma Hepatocelular/complicações , Humanos , Neoplasias Hepáticas/complicações , Masculino , Pessoa de Meia-Idade , Osteonecrose/complicações , Osteonecrose/diagnóstico por imagem , Dor/complicações , Pancreatite Crônica/complicações , Veia Porta , Trombose Venosa/complicações
12.
Indian Pacing Electrophysiol J ; 22(5): 254-257, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35870802

RESUMO

Torsade de Pointes (TdP) can be triggered by a pacing spike on the T-wave, due to pacemaker undersensing. However, it is not widely known that this phenomenon can occur even during pacemaker implantation. An 84-year-old woman underwent pacemaker implantation for the treatment of a complete atrioventricular block with dyspnea. During the procedure, immediately following ventricular lead insertion and before torque wrench tightening, TdP was observed. Ventricular pacing was initiated by inserting the lead into the header of the generator; however, sensing remained unstable. T-waves associated with undersensed PVCs and ventricular pacing occurred simultaneously, resulting in a spike on the T-wave and TdP.

13.
J Viral Hepat ; 29(7): 543-550, 2022 07.
Artigo em Inglês | MEDLINE | ID: mdl-35499194

RESUMO

The risk of hepatocellular carcinoma (HCC) occurrence following hepatitis C virus (HCV) eradication has been previously reported, but the impact of HCV eradication on advanced HCC patient survival remains unclear. Therefore, the present study aimed to evaluate the effect of HCV eradication on the survival outcome of patients with advanced HCC treated with sorafenib. One hundred and three HCV-related advanced HCC patients who were treated with sorafenib were enrolled in this study. Of these, 43 patients were administered antiviral therapy before sorafenib treatment (HCV eradication group), while 60 patients remained HCV-infected (HCV non-eradication group). We analysed the impact of HCV eradication on survival in advanced HCC treated with sorafenib. Median overall survival (OS) was significantly longer in the HCV eradication group than in the HCV non-eradication group (24.0 months vs. 14.1 months; p = 0.001). Although there was no significant difference in the albumin-bilirubin (ALBI) score at the start of treatment between the HCV eradication group and the non-eradication group (p = 0.065), the ALBI score at 2 months after initiation of sorafenib treatment was significantly decreased in the HCV non-eradication group (p < 0.001), but not in the HCV eradication group (p = 0.121). Multivariate logistic analysis revealed HCV eradication (hazard ratio [HR], 0.5; p = 0.006) and ALBI score at the start of treatment (HR, 2.47; p = 0.002) as factors that may contribute to OS. HCV eradication may serve an important role in the survival outcome of advanced HCC patients treated with sorafenib.


Assuntos
Antineoplásicos , Carcinoma Hepatocelular , Hepatite C , Neoplasias Hepáticas , Antineoplásicos/uso terapêutico , Bilirrubina , Hepacivirus/genética , Hepatite C/complicações , Hepatite C/tratamento farmacológico , Humanos , Neoplasias Hepáticas/patologia , Prognóstico , Estudos Retrospectivos , Sorafenibe/uso terapêutico
15.
World J Clin Cases ; 10(3): 1000-1007, 2022 Jan 21.
Artigo em Inglês | MEDLINE | ID: mdl-35127913

RESUMO

BACKGROUND: Intraductal papillary neoplasm of the bile duct (IPNB) rarely recurs in a multicentric manner. We encountered a patient with multiple recurrences of the gastric subtype of IPNB one year after spontaneous detachment of the primary tumor during peroral cholangioscopy (POCS). CASE SUMMARY: A 68-year-old woman on maintenance hemodialysis because of lupus nephritis had several cardiovascular diseases and a pancreatic intraductal papillary mucinous neoplasm (IPMN). She was referred to our department for dilation of the common bile duct (CBD) and a tumor in the lumen, detected using ultrasonography. She had no complaints, and blood tests of hepatobiliary enzymes were normal. Magnetic resonance cholangiopancreatography (MRCP) showed a papillary tumor in the CBD with a filling defect detected using endoscopic retrograde cholangiography (ERC). Intraductal ultrasonography revealed a papillary tumor and stalk at the CBD. During POCS, the tumor spontaneously detached with its stalk into the CBD. Pathology showed low-intermediate nuclear atypia of the gastric subtype of IPNB. After 1 year, follow-up MRCP showed multiple tumors distributed from the left hepatic duct to the CBD. ERC and POCS showed multicentric tumors. She was alive without hepatobiliary symptoms at least two years after initial diagnosis of IPNB. CONCLUSION: The patient experienced gastric subtype of IPNB without curative resection. Observation may be reasonable for patients with this subtype.

16.
Mol Clin Oncol ; 16(2): 53, 2022 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-35070302

RESUMO

Previous studies have reported that hepatocellular carcinoma (HCC) harboring WNT/ß-catenin mutations exhibits iso-high intensity by gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid-enhanced magnetic resonance imaging (Gd-EOB-DTPA-MRI, i.e. EOB-MRI) during the hepatobiliary phase (HBP), thus indicating that EOB-MRI may help clinicians identify an immune exclusion class, which might not respond to treatment with immune checkpoint inhibitors. The present study analyzed the efficacy of lenvatinib for HCC with iso-high intensity during the HBP of EOB-MRI. Overall, 52 patients who underwent EOB-MRI for 140 HCC nodules were classified into iso-high-intensity and low-intensity groups during the HBP of EOB-MRI. The clinical and histological characteristics, and different responses to treatment of both groups were analyzed. The expression levels of ß-catenin and glutamine synthetase, indicative of WNT/ß-catenin mutations, were enhanced in the HCC with iso-high-intensity group. Nine patients had iso-high intensity, whereas 43 patients had low intensity. Tumor size was larger, and the levels of antagonist-II or vitamin K absence were higher in the iso-high-intensity group. Furthermore, 3/9 patients in the iso-high-intensity group had objective responses compared with 13/43 patients in the low-intensity group. Disease control was observed in 5/9 patients in the iso-high-intensity group and 26/43 patients in the low-intensity group. Median overall survival was 29.8 months for the iso-high-intensity group compared with 20.8 months for the low-intensity group. In the iso-high-intensity group, the median progression-free survival rate was 6.7 months compared with 5.6 months in the low-intensity group. No differences in best percentage change from baseline tumor size were observed in either group. Although few patients were included in this study, the present findings suggested that the efficacy of lenvatinib was unaffected by signal intensity during the HBP of EOB-MRI.

17.
J Viral Hepat ; 29(1): 35-42, 2022 01.
Artigo em Inglês | MEDLINE | ID: mdl-34661320

RESUMO

Direct-acting antivirals (DAAs) have recently been developed to treat hepatitis C virus (HCV) infection, and interferon-free DAA treatment has improved liver function of HCV patients. The risk of hepatocellular carcinoma (HCC) occurrence following HCV eradication has been previously reported, but HCC may have been missed following imaging diagnosis before DAA administration in previous studies. Therefore, the present study aimed to identify definite predictors of HCC occurrence ≥1 year after DAA treatment. Among 956 patients receiving DAAs for HCV infection, 567 patients who achieved sustained virologic response with no history of HCC treatment were enrolled in this study between September 2014 and July 2021. The incidence of HCC in HCV-infected patients ≥1 year following DAA treatment, and the predictors contributing to HCC occurrence were identified using clinical characteristics and blood test results. In the present study, 25 patients developed HCC. The incidence of HCC was 1.4%, 3.2%, 4.9% and 6.8% at 2, 3, 4 and 5 years, respectively, from the end of treatment with DAAs. Multivariate logistic analysis revealed serum α-fetoprotein level at end of treatment (EOT-AFP) >3.8 ng/ml ≥1 year following treatment with DAAs (HR, 9.7; p < .0001) as an independent factor that may contribute to HCC occurrence following DAA treatment. In conclusion, serum EOT-AFP level may serve an important role in determining the risk of HCC occurrence ≥1 year after DAA treatment. Regular examinations are required even if serum EOT-AFP level is low at treatment completion.


Assuntos
Carcinoma Hepatocelular , Hepatite C Crônica , Hepatite C , Neoplasias Hepáticas , Antivirais/uso terapêutico , Carcinoma Hepatocelular/tratamento farmacológico , Carcinoma Hepatocelular/epidemiologia , Carcinoma Hepatocelular/prevenção & controle , Hepacivirus , Hepatite C/complicações , Hepatite C/tratamento farmacológico , Hepatite C/epidemiologia , Hepatite C Crônica/complicações , Hepatite C Crônica/tratamento farmacológico , Humanos , Neoplasias Hepáticas/tratamento farmacológico , Neoplasias Hepáticas/epidemiologia , Neoplasias Hepáticas/prevenção & controle , Fatores de Risco , Resposta Viral Sustentada , alfa-Fetoproteínas
18.
Intern Med ; 61(8): 1163-1167, 2022 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-34565779

RESUMO

A 54-year-old man was admitted to our hospital due to intermittent chest pain. He had a history of acute myocardial infarction, and peri-stent contrast staining had been observed at the stent implantation site. The patient previously underwent anticoagulation therapy for left ventricular thrombus and antiplatelet therapy to prevent stent thrombosis. More than one year after implantation of a drug-eluting stent, antiplatelet drugs were discontinued, and anticoagulant alone was prescribed according to the guidelines, which resulted in very late stent thrombosis. The risks of both bleeding and thrombosis must be fully considered when deciding whether or not to discontinue antiplatelet therapy during anticoagulation therapy.


Assuntos
Stents Farmacológicos , Trombose , Anticoagulantes/efeitos adversos , Stents Farmacológicos/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Inibidores da Agregação Plaquetária/uso terapêutico , Coloração e Rotulagem , Stents , Trombose/tratamento farmacológico , Trombose/etiologia
19.
CJC Open ; 3(11): 1357-1364, 2021 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-34901804

RESUMO

BACKGROUND: Patients undergoing percutaneous coronary intervention (PCI) often develop atrial fibrillation (AF). We investigated the clinical effects of AF status on in-hospital mortality and complications in patients with PCI using a recent large-scale nationwide dataset. METHODS: Using a claims-based dataset from 1022 hospitals in Japan for the time period between 2012 and 2016, patients with PCI were identified and classified into 3 groups according to AF status: no AF, prevalent AF before admission, and incident AF after admission. In-hospital mortality, complications, and medical costs were compared in crude and propensity-matched cohorts. RESULTS: In 659,525 hospitalized patients undergoing PCI, prevalent AF and incident AF were observed in 6.0% and 1.3% patients, respectively; the AF rates increased over 5 years. A greater proportion of older patients and patients with comorbidities had both of these categories of AF; undergoing PCI for acute coronary syndrome was common in incident AF. Both prevalent AF and incident AF were associated with worse crude outcomes and complications during hospitalization. In propensity-matched cohorts, incident AF was associated with a higher in-hospital mortality rate, longer length of stay, higher direct costs, and higher rate of complications, including stroke and acute kidney injury, compared with prevalent AF. These outcomes, except length of in-hospital stay, did not change for either AF status over 5 years. CONCLUSIONS: Prevalent AF and incident AF in patients undergoing PCI were both associated with deteriorating crude outcomes and complications; in particular, incident AF was associated with worse adjusted outcomes and complications. Further efforts are needed to improve patient outcomes in an aging society in which the incidence of AF is increasing.


CONTEXTE: Une fibrillation auriculaire (FA) apparaît souvent chez les patients qui subissent une intervention coronarienne percutanée (ICP). Nous avons étudié les effets cliniques de l'état de la FA sur la mortalité à l'hôpital et les complications chez les patients ayant subi une ICP en utilisant un ensemble de données nationales récentes à grande échelle. MÉTHODOLOGIE: À partir d'un ensemble de données basées sur les demandes de règlement de 1022 hôpitaux au Japon pour la période allant de 2012 à 2016, les patients ayant subi une ICP ont été ciblés et classés en 3 groupes selon l'état de la FA : FA absente, FA présente avant l'admission, et nouvelle FA après l'admission. La mortalité à l'hôpital, les complications et les coûts médicaux ont été comparés dans des cohortes brutes et des cohortes appariées par score de propension. RÉSULTATS: Sur 659 525 patients hospitalisés ayant subi une ICP, une FA déjà présente et une nouvelle FA ont été observées chez 6,0 % et 1,3 % des patients, respectivement; les taux de FA ont augmenté sur 5 ans. Une plus grande proportion de patients plus âgés et de patients ayant des comorbidités présentaient ces deux catégories de FA; le fait de subir une ICP pour un syndrome coronarien aigu était fréquent chez les patients présentant une nouvelle FA. La FA déjà présente et la nouvelle FA étaient toutes deux associées à des résultats bruts et à des complications plus graves pendant l'hospitalisation. Dans les cohortes appariées par score de propension, la nouvelle FA était associée à un taux de mortalité à l'hôpital plus élevé, à une durée de séjour plus longue, à des coûts directs plus importants et à un taux plus élevé de complications, notamment d'accidents vasculaires cérébraux et de lésions rénales aiguës, par rapport à la FA déjà présente. Ces résultats, à l'exception de la durée du séjour à l'hôpital, n'ont pas changé pour les deux états de la FA sur 5 ans. CONCLUSIONS: La FA déjà présente et la nouvelle FA chez les patients subissant une ICP étaient toutes deux associées à une détérioration des résultats bruts et à des complications; plus particulièrement, la nouvelle FA était associée à de moins bons résultats ajustés et à de pires complications. Des efforts supplémentaires sont nécessaires pour améliorer les résultats des patients dans une société vieillissante où l'incidence de la FA augmente.

20.
BMC Res Notes ; 14(1): 452, 2021 Dec 18.
Artigo em Inglês | MEDLINE | ID: mdl-34922617

RESUMO

OBJECTIVE: We recently developed the self-management system using the HF points and instructions to visit hospitals or clinics when the points exceed the pre-specified levels. We found that the self-management system decreased the hospitalization for HF with an increase in unplanned visits and early intervention in the outpatient department. However, it is unclear whether we managed severe HF outpatients who should have been hospitalized. In this study, we aimed to compare HF severity in rehospitalized patients with regard to self-management system use. RESULTS: We retrospectively enrolled 306 patients (153 patients each in the system user and non-user groups) using propensity scores (PS). We compared HF severity and length of readmission in rehospitalized patients in both groups. During the 1-year follow-up period, 24 system users and 43 non-system users in the PS-matched cohort were hospitalized. There were no significant differences between the groups in terms of brain natriuretic peptide levels at readmission, maximum daily intravenous furosemide dose, percentage of patients requiring intravenous inotropes, duration of hospital stay and in-hospital mortality. These results suggest that the HF severity in rehospitalized patients was not different between the two groups.


Assuntos
Insuficiência Cardíaca , Autogestão , Insuficiência Cardíaca/terapia , Humanos , Readmissão do Paciente , Estudos Retrospectivos , Índice de Gravidade de Doença
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...